- Home
- STTK vs OBE Comparison
STTK vs OBE Comparison
Compare STTK & OBE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STTK | OBE |
|---|---|---|
| Founded | 2016 | 1979 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 538.3M | 526.9M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | STTK | OBE |
|---|---|---|
| Price | $6.10 | $12.28 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 1 |
| Target Price | $10.00 | $10.00 |
| AVG Volume (30 Days) | 522.7K | ★ 1.2M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.21 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.71 | $4.77 |
| 52 Week High | $8.33 | $14.59 |
Technical Indicators
Market Signals| Indicator | STTK | OBE |
|---|---|---|
| Relative Strength Index (RSI) | 42.55 | 49.16 |
| Support Level | $5.85 | $11.55 |
| Resistance Level | $6.81 | $14.59 |
| Average True Range (ATR) | 0.52 | 0.64 |
| MACD | -0.12 | -0.26 |
| Stochastic Oscillator | 23.03 | 25.16 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Sale of Oil.